PL3186244T3 - Analogi dioksolanowe urydyny w leczeniu raka - Google Patents
Analogi dioksolanowe urydyny w leczeniu rakaInfo
- Publication number
- PL3186244T3 PL3186244T3 PL15756888T PL15756888T PL3186244T3 PL 3186244 T3 PL3186244 T3 PL 3186244T3 PL 15756888 T PL15756888 T PL 15756888T PL 15756888 T PL15756888 T PL 15756888T PL 3186244 T3 PL3186244 T3 PL 3186244T3
- Authority
- PL
- Poland
- Prior art keywords
- dioxolate
- uridine
- analogs
- cancer
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1450983 | 2014-08-25 | ||
| SE1550858 | 2015-06-22 | ||
| EP15756888.2A EP3186244B1 (en) | 2014-08-25 | 2015-08-24 | Dioxolane analogues of uridine for the treatment of cancer |
| PCT/EP2015/069370 WO2016030335A1 (en) | 2014-08-25 | 2015-08-24 | Dioxolane analogues of uridine for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3186244T3 true PL3186244T3 (pl) | 2020-11-16 |
Family
ID=54014804
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15756888T PL3186244T3 (pl) | 2014-08-25 | 2015-08-24 | Analogi dioksolanowe urydyny w leczeniu raka |
| PL19177824.0T PL3572410T3 (pl) | 2014-08-25 | 2015-08-24 | Analogi dioksolanowe urydyny w leczeniu raka |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19177824.0T PL3572410T3 (pl) | 2014-08-25 | 2015-08-24 | Analogi dioksolanowe urydyny w leczeniu raka |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US10144750B2 (esLanguage) |
| EP (2) | EP3186244B1 (esLanguage) |
| JP (2) | JP6663424B2 (esLanguage) |
| KR (2) | KR102398714B1 (esLanguage) |
| CN (4) | CN111269264A (esLanguage) |
| AU (2) | AU2015308988C1 (esLanguage) |
| BR (1) | BR112017003898B1 (esLanguage) |
| CA (2) | CA2956251C (esLanguage) |
| CY (1) | CY1122945T1 (esLanguage) |
| DK (2) | DK3572410T3 (esLanguage) |
| EA (2) | EA031106B1 (esLanguage) |
| ES (2) | ES2927212T3 (esLanguage) |
| HR (1) | HRP20201023T1 (esLanguage) |
| HU (2) | HUE059640T2 (esLanguage) |
| IL (2) | IL250344B (esLanguage) |
| MX (1) | MX369649B (esLanguage) |
| MY (2) | MY188089A (esLanguage) |
| NZ (2) | NZ729118A (esLanguage) |
| PH (2) | PH12017500184A1 (esLanguage) |
| PL (2) | PL3186244T3 (esLanguage) |
| PT (2) | PT3186244T (esLanguage) |
| SG (3) | SG11201701172SA (esLanguage) |
| WO (1) | WO2016030335A1 (esLanguage) |
| ZA (1) | ZA201802864B (esLanguage) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3186244T (pt) * | 2014-08-25 | 2020-05-29 | Medivir Ab | Análogos dioxolano de uridina para o tratamento de cancro |
| CN106543220A (zh) * | 2015-09-16 | 2017-03-29 | 博瑞生物医药（苏州）股份有限公司 | 氨基磷酸酯化合物及其制备方法和晶体 |
| HRP20211812T1 (hr) * | 2015-12-11 | 2022-03-04 | NuCana plc | Dijastereoselektivna sinteza derivata fosfata i prolijeka gemcitabina nuc-1031 |
| KR102703122B1 (ko) * | 2016-03-02 | 2024-09-04 | 메디비르 아크티에보라그 | 소라페닙 또는 레고라페닙과 트록사시타빈의 포스포라미데이트 전구약물의 병용 요법 |
| CN106432328B (zh) * | 2016-09-14 | 2019-03-22 | 江苏福瑞生物医药有限公司 | 一种索非布韦中间体的制备方法 |
| WO2018091633A1 (en) * | 2016-11-18 | 2018-05-24 | Neurovive Pharmaceutical Ab | Liver prodrugs of mitochondrial proton ionophores |
| GB201709471D0 (en) * | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| WO2019245444A1 (en) | 2018-06-21 | 2019-12-26 | Medivir Ab | Base-modified cytidine nucleotides for leukemia therapy |
| JP7337539B2 (ja) * | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
| WO2020171757A1 (en) * | 2019-02-18 | 2020-08-27 | Medivir Aktiebolag | Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-pd1 or anti-pdl1 monoclonal antibody |
| CN110964057B (zh) * | 2019-12-25 | 2022-05-06 | 东南大学 | 一种利用微流体反应装置制备索非布韦中间体的方法 |
| CN113402546A (zh) * | 2020-03-17 | 2021-09-17 | 浙江四维医药科技有限公司 | 一种瑞德西韦磷酸中间体尾链动态动力学拆分方法 |
| TW202200140A (zh) * | 2020-04-15 | 2022-01-01 | 瑞典商米迪維艾克提伯拉公司 | 用於肝癌之miv-818/樂伐替尼(lenvatinib)組合療法 |
| CN113754692B (zh) * | 2020-06-03 | 2022-06-10 | 上海交通大学 | 瑞德西韦中间体(s,s)-氨基磷酸酯的不对称催化合成方法 |
| CN114685558A (zh) * | 2020-12-28 | 2022-07-01 | 尚科生物医药（上海）有限公司 | 一种瑞德西韦中间体的制备方法 |
| CN114249764A (zh) * | 2021-11-10 | 2022-03-29 | 宁波大学 | 一种磷酰胺酯类前药的中间体及其制备方法与应用 |
| WO2025155547A1 (en) * | 2024-01-17 | 2025-07-24 | University Of Georgia Research Foundation, Inc. | An efficient synthesis of beta-l-5-[(e)-2-bromovinyl)-1-((2s,4s)-2-(hydroxymethyl)-1,3-(dioxolane-4-yl) uracil)] (l-bhdu) via chiral pure l-dioxolane |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
| US6022876A (en) | 1996-11-15 | 2000-02-08 | Yale University | L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections |
| US20030013660A1 (en) * | 2000-10-13 | 2003-01-16 | Shire Biochem Inc. | Dioxolane analogs for improved inter-cellular delivery |
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| WO2007106450A2 (en) * | 2006-03-10 | 2007-09-20 | University Of Georgia Research Foundation, Inc. | Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy |
| KR20090057050A (ko) | 2006-09-01 | 2009-06-03 | 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 | 암치료를 위한 트록사시타빈 전구약물 |
| PL216525B1 (pl) * | 2006-10-17 | 2014-04-30 | Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk | 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów |
| US20130143835A1 (en) * | 2011-12-05 | 2013-06-06 | Medivir Ab | HCV Polymerase Inhibitors |
| MX2016006919A (es) * | 2013-11-27 | 2016-08-17 | Idenix Pharmaceuticals Llc | Nucleotidos para el tratamiento de cancer de higado. |
| PT3186244T (pt) * | 2014-08-25 | 2020-05-29 | Medivir Ab | Análogos dioxolano de uridina para o tratamento de cancro |
-
2015
- 2015-08-24 PT PT157568882T patent/PT3186244T/pt unknown
- 2015-08-24 ES ES19177824T patent/ES2927212T3/es active Active
- 2015-08-24 CN CN202010199579.4A patent/CN111269264A/zh active Pending
- 2015-08-24 WO PCT/EP2015/069370 patent/WO2016030335A1/en not_active Ceased
- 2015-08-24 CA CA2956251A patent/CA2956251C/en active Active
- 2015-08-24 BR BR112017003898-6A patent/BR112017003898B1/pt active IP Right Grant
- 2015-08-24 EA EA201790328A patent/EA031106B1/ru not_active IP Right Cessation
- 2015-08-24 CA CA3128645A patent/CA3128645C/en active Active
- 2015-08-24 KR KR1020207008682A patent/KR102398714B1/ko active Active
- 2015-08-24 CN CN201911149251.5A patent/CN110804072B/zh active Active
- 2015-08-24 EP EP15756888.2A patent/EP3186244B1/en active Active
- 2015-08-24 CN CN201580056640.7A patent/CN107074826B/zh active Active
- 2015-08-24 AU AU2015308988A patent/AU2015308988C1/en active Active
- 2015-08-24 SG SG11201701172SA patent/SG11201701172SA/en unknown
- 2015-08-24 EA EA201890648A patent/EA033300B1/ru not_active IP Right Cessation
- 2015-08-24 CN CN201911148331.9A patent/CN110790789B/zh active Active
- 2015-08-24 MY MYPI2017700615A patent/MY188089A/en unknown
- 2015-08-24 MX MX2017002328A patent/MX369649B/es active IP Right Grant
- 2015-08-24 PL PL15756888T patent/PL3186244T3/pl unknown
- 2015-08-24 ES ES15756888T patent/ES2796089T3/es active Active
- 2015-08-24 SG SG10202001117YA patent/SG10202001117YA/en unknown
- 2015-08-24 KR KR1020177008235A patent/KR102396905B1/ko active Active
- 2015-08-24 JP JP2017511226A patent/JP6663424B2/ja active Active
- 2015-08-24 PT PT191778240T patent/PT3572410T/pt unknown
- 2015-08-24 NZ NZ729118A patent/NZ729118A/en unknown
- 2015-08-24 DK DK19177824.0T patent/DK3572410T3/da active
- 2015-08-24 SG SG10201911558UA patent/SG10201911558UA/en unknown
- 2015-08-24 HU HUE19177824A patent/HUE059640T2/hu unknown
- 2015-08-24 DK DK15756888.2T patent/DK3186244T3/da active
- 2015-08-24 EP EP19177824.0A patent/EP3572410B1/en active Active
- 2015-08-24 PL PL19177824.0T patent/PL3572410T3/pl unknown
- 2015-08-24 US US15/506,692 patent/US10144750B2/en active Active
- 2015-08-24 HU HUE15756888A patent/HUE050705T2/hu unknown
- 2015-08-24 HR HRP20201023TT patent/HRP20201023T1/hr unknown
- 2015-08-24 NZ NZ762628A patent/NZ762628A/en unknown
-
2017
- 2017-01-30 IL IL250344A patent/IL250344B/en active IP Right Grant
- 2017-01-31 PH PH12017500184A patent/PH12017500184A1/en unknown
- 2017-02-22 MY MYPI2021007010A patent/MY198325A/en unknown
-
2018
- 2018-03-20 AU AU2018201980A patent/AU2018201980B2/en active Active
- 2018-05-02 ZA ZA2018/02864A patent/ZA201802864B/en unknown
- 2018-12-03 US US16/208,083 patent/US10336780B2/en active Active
-
2019
- 2019-05-21 IL IL266766A patent/IL266766B/en active IP Right Grant
- 2019-07-01 US US16/459,165 patent/US10654877B2/en active Active
- 2019-08-19 PH PH12019501919A patent/PH12019501919A1/en unknown
-
2020
- 2020-02-14 JP JP2020023051A patent/JP6905609B2/ja active Active
- 2020-04-13 US US16/847,477 patent/US10822360B2/en active Active
- 2020-05-22 CY CY20201100469T patent/CY1122945T1/el unknown
- 2020-11-02 US US17/087,483 patent/US11447511B2/en active Active
-
2022
- 2022-09-19 US US17/948,050 patent/US20230117570A1/en not_active Abandoned
-
2023
- 2023-05-31 US US18/326,992 patent/US20230382931A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL296080B1 (en) | Method for treating cancer | |
| IL255261A0 (en) | Methods for treating cancer | |
| PL3186244T3 (pl) | Analogi dioksolanowe urydyny w leczeniu raka | |
| PL3265053T3 (pl) | Sposoby leczenia skóry | |
| HUE059694T2 (hu) | Készítmény rák kezelésére | |
| PL3283527T3 (pl) | Leczenie skojarzone nowotworów | |
| PL3157512T3 (pl) | Zastosowanie kannabidioli w leczeniu padaczki | |
| IL251890A0 (en) | Combination immunotherapy approach for treatment of cancer | |
| DK3240801T3 (da) | Kombinationstumorimmunterapi | |
| HUE054012T2 (hu) | Kombinációs terápia rák ellen | |
| PL3197456T3 (pl) | Leczenie nowotworów | |
| IL254251A0 (en) | Human fibrolamellar hepatocellular carcinomas (hfl-hccs) | |
| DK3778595T3 (da) | Pancreatitisbehandling | |
| HUE050944T2 (hu) | Kezelési eljárás tradipitant alkalmazásával | |
| IL242971B (en) | Ventricular far field reduction | |
| IL256206A (en) | Mct4 inhibitors for treating disease | |
| PL3236960T3 (pl) | Fluralaner do zastosowania w leczeniu demodekozy | |
| PT3134119T (pt) | Tratamento do cancro | |
| IL251903B (en) | Apilimod for use in the treatment of colorectal cancer | |
| SI3188599T1 (sl) | Zdravljenje na osnovi anamorelina | |
| DK3393478T3 (da) | Kombinationsterapi | |
| EP3362091A4 (en) | COMBINATION THERAPY | |
| HUE054998T2 (hu) | Kombinációs terápiák emlõrák kezelésében való alkalmazásra | |
| DK3302478T3 (da) | Pac-1 kombinations behandling | |
| IL255560B (en) | Macropinocytosis in cancer |